首页> 外文期刊>Therapeutic Drug Monitoring >Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study.
【24h】

Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study.

机译:快速和延长释放药物给药后,汗液测试对检测哌醋甲酯的有用性:一项试点研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The pharmacokinetics of methylphenidate (MPH), a prescription amphetamine derivative used in the treatment of attention-deficit hyperactivity disorder, has been amply described in conventional biological matrices. Recently, the excretion of MPH and its principal metabolite, ritalinic acid (RA) in oral fluid and plasma after a single drug administration has been described. The aim of this study was to describe the excretion of MPH and RA in sweat after the administration of a single dose of either fast-release or extended-release MPH. Three male subjects received 2 simultaneous oral doses of 10 mg fast-release MPH, and 1 male subject received one dose of 20 mg extended-release MPH. Sweat patches were applied to the back of each participant and removed at timed intervals. MPH and RA were determined in patches using a previously validated liquid chromatography-electrospray ionization mass spectrometric method. MPH was detected in sweat after the administration of fast- and extended-release formulations. For the fast-release formulation, MPH appeared in the sweat patches 2 hours after administration with a maximum of 15.9 nanogram per patch, reached after 24 hours. Mean total MPH excreted was 0.02 mg (about 0.08% of the administered dose). For the extended-release formulation, MPH appeared in the sweat 5 hours after administration and reached a maximum of 34.3 nanogram per patch after 24 hours. Mean total MPH excreted was 0.04 mg (about 0.18% of the administered dose). RA was not detected in either of the sweat patches probably because of its acidic properties. Measuring MPH in sweat patches can be a viable alternative to urine testing for noninvasive monitoring of use and misuse of the drug.
机译:在传统的生物基质中已充分描述了哌醋甲酯(MPH)的药代动力学,这是一种用于治疗注意力不足过动症的苯丙胺衍生物。最近,已经描述了单药给药后MPH及其主要代谢产物利他林酸(RA)在口腔液和血浆中的排泄。这项研究的目的是描述单剂量快速释放或延长释放的MPH给药后汗液中MPH和RA的排泄。 3名男性受试者同时接受2剂口服口服10毫克速释MPH,1名男性受试者接受1剂20毫克缓释MPH。将汗斑贴在每个参与者的背部,并在一定的时间间隔内将其去除。使用先前已验证的液相色谱-电喷雾电离质谱法在补丁中测定MPH和RA。服用速释和缓释制剂后,汗液中检测到了MPH。对于速释制剂,MPH在给药后2小时出现在出汗斑块中,每个斑块最多出现15.9纳克,到24小时后达到。平均总MPH排出量为0.02 mg(约占给药剂量的0.08%)。对于缓释制剂,MPH在给药后5小时出现在汗液中,并且在24小时后达到最大34.3纳克/贴剂。平均总MPH排出量为0.04 mg(约占给药剂量的0.18%)。在两个汗斑中均未检测到RA,可能是由于其酸性。测量出汗斑中的MPH可以替代尿液检测,以无创地监测药物的使用和滥用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号